|
| Home : Eloxx Pharmacueticals Receives A US$5 Million Investment from Quark Venture and GF Securities to Advance A Novel Disease-Modifying Therapy Targeting Genetic Diseases |
|
Jun 09
2017 |
Eloxx Pharmacueticals Receives A US$5 Million Investment from Quark Venture and GF Securities to Advance A Novel Disease-Modifying Therapy Targeting Genetic Diseases |
|
VANCOUVER, BRITISH COLUMBIA--(Marketwired - June 8, 2017) - Today, Quark Venture Inc. and GF Securities announced a $US5 million investment Eloxx Pharmaceuticals through their Global Health Science Fund. This investment is part of a US$24 million financing Series C round led by Pontifax, a leading VC in the Life Sciences arena and co-founder of Eloxx Pharmaceuticals. Headquartered in Rehovot, Israel, Eloxx Pharmaceuticals is a clinical stage company developing first in class therapeutics to treat genetic diseases caused by non-sense mutations. |
|
|
|
| Source:http://www.marketwired.com/mw/release.do?id=2220964&sourceType=3 |
| |
|
Related News
|
» North American Nickel Announces Closing of Equity Financing
» ANALYSIS: Comey goes nuclear in showdown with Trump
|
|
|
